Evidence map›Paper›PMID 40017371›Full record

ArticleStatistical methods in medical research2025

A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time.

Can Xie, Xuelin Huang, Ruosha Li, Yu Shen, Nicholas J Short, Kapil N Bhalla

Abstract read
In one paragraph

Article in Statistical methods in medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Can XieDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4170-1247
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1192-9336
Ruosha LiDepartment of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0003-3595-4392
Yu ShenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kapil N BhallaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Susan K Peterson · 2002 to 2026
$23.8M
Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum - SupplementU01CA253911 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALAGOZ, OGUZHAN, DE KONING, HARRY J · 2020 to 2025
$10.6M
Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individualR01CA272806 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Xuelin Huang · 2023 to 2026
$1.5M
Modeling and Validation for Tackling Risk Prediction with Competing Risks by Integrating Multiple Longitudinal BiomarkersR01DK117209 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, RUOSHA · 2018 to 2021
$1.4M
Statistical methods for regression modeling of global percentile outcome in neurological diseasesR03NS108136 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, RUOSHA · 2019 to 2020
$169k
NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA272806NCI NIH HHS U01 CA253911NCI NIH HHS U54 CA096300NIDDK NIH HHS R01 DK117209NINDS NIH HHS R03 NS108136
6 · The paper itself

Abstract

With the advancement of medical treatments, many historically incurable diseases have become curable. An accurate estimation of the cure rates is of great interest. When there are no clear biomarker indicators for cure, the estimation of cure rate is intertwined with and influenced by the specification of hazard functions for uncured patients. Consequently, the commonly used proportional hazards (PH) assumption, when violated, may lead to biased cure rate estimation. Meanwhile, longitudinal biomarker measurements for individual patients are usually available. To accommodate non-PH functions and incorporate individual longitudinal biomarker trajectories, we propose a new joint model for cure, survival, and longitudinal data, with hazard ratios between different covariate subgroups flexibly varying over time. The proposed joint model has individual random effects shared between its longitudinal and cure-survival submodels. The regression parameters are estimated by maximization of the non-parametric likelihood via the Monte Carlo expectation-maximization algorithm. The standard error estimation applies a jackknife resampling method. In simulation studies, we consider crossing and non-crossing survival curves, and the proposed model provides unbiased estimates for the cure rates. Our proposed joint cure model is illustrated via a study of chronic myeloid leukemia.

Indexed as

Models, StatisticalAlgorithmsBiomarkersComputer SimulationHumansLikelihood FunctionsLongitudinal StudiesMonte Carlo MethodProportional Hazards ModelsSurvival AnalysisBiomarkersCure modeljoint modelinglinear mixed modellongitudinal datanon-proportional hazardssurvival analysis

Identifiers

PMID40017371
PMCPMC12075895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.